<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03524677</url>
  </required_header>
  <id_info>
    <org_study_id>17_D'Angelo</org_study_id>
    <nct_id>NCT03524677</nct_id>
  </id_info>
  <brief_title>Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Borderline Resectable Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis</brief_title>
  <official_title>Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Borderline Resectable Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sant'Andrea University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Borderline resectable pancreatic cancers represent a wide spectrum of final histologic
      stages. A patient-tailored treatment plan requires an accurate preoperative staging.
      Currently more than 40% of patient taken to the OR are actually unresectable and more than
      one third of resected patient will need a vascular resection, of those approximately an half
      will eventually have a vascular infiltration.

      Among patients that meet upfront surgery some would have benefit of a neoadjuvant treatment
      and vice versa. Accuracy of preoperative staging is of primary importance in treatment
      decisional making. Due to its location, invasive preoperative diagnostic tests on pancreatic
      cancer are expensive and risky. Liquid biopsy provides a non-invasive signature of the tumor.
      Analyzing mutations on cell-free nucleic acids gives translational information on tumor
      biology and therefore on its clinic-pathological features and likely on its progression. This
      study would be the first -in our knowledge- analyzing the relationship of a pattern of 4
      major genes involved in pancreatic cancer progression on liquid biopsy and the T-stage, with
      particular attention to vascular invasion. A properly staged patient provides a better
      resource allocation, an optimal treatment plan and improves patient's outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular Invasion</measure>
    <time_frame>within one month from recruiting</time_frame>
    <description>Presence of venous and/or arterial invasion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years follow up</time_frame>
    <description>Time to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3 years follow up</time_frame>
    <description>Time to relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N stage</measure>
    <time_frame>withn one month from recruiting</time_frame>
    <description>Presence of locoregional nodes' metastasis</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Borderline resectable pancreatic cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic pancreatic cancer</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Liquid Biopsy</intervention_name>
    <description>K-RAS, CDKN2A, SMAD4 and TP53 mutation on circulating cfDNA</description>
    <arm_group_label>Borderline resectable pancreatic cancer</arm_group_label>
    <arm_group_label>Metastatic pancreatic cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Immunohistochemestry</intervention_name>
    <description>CDKN2A, SMAD4 and TP53 detection on tissue</description>
    <arm_group_label>Borderline resectable pancreatic cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients affected by Borderline resectable Pancreatic Cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Borderline resectable Pancreatic Cancer

        Exclusion Criteria:

          -  &lt;18y
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Ramacciato, MD, FACS</last_name>
    <role>Study Chair</role>
    <affiliation>Sapieza University of Rome (IT)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Antolino, MD, PhD stud</last_name>
    <phone>+393470409876</phone>
    <email>laura.antolino@uniroma1.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francesco D'Angelo, MD, PhD</last_name>
    <phone>+390633775632</phone>
    <email>francesco.dangelo@uniroma1.it</email>
  </overall_contact_backup>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2018</study_first_submitted>
  <study_first_submitted_qc>May 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2018</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Laura Antolino</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>liquid biopsy</keyword>
  <keyword>borderline resectable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

